Correlation Between Morgan Stanley and Abcellera Biologics

Can any of the company-specific risk be diversified away by investing in both Morgan Stanley and Abcellera Biologics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Morgan Stanley and Abcellera Biologics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Morgan Stanley and Abcellera Biologics, you can compare the effects of market volatilities on Morgan Stanley and Abcellera Biologics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Morgan Stanley with a short position of Abcellera Biologics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Morgan Stanley and Abcellera Biologics.

Diversification Opportunities for Morgan Stanley and Abcellera Biologics

0.72

Correlation Coefficient

Morgan Stanley  Abcellera Biologics

Poor diversification

The 3 months correlation between Morgan and Abcellera is 0.72. Overlapping area represents the amount of risk that can be diversified away by holding Morgan Stanley and Abcellera Biologics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Abcellera Biologics and Morgan Stanley is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Morgan Stanley are associated (or correlated) with Abcellera Biologics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Abcellera Biologics has no effect on the direction of Morgan Stanley i.e., Morgan Stanley and Abcellera Biologics go up and down completely randomly.

Pair Corralation between Morgan Stanley and Abcellera Biologics

Allowing for the 90-day total investment horizon Morgan Stanley is expected to generate 0.56 times more return on investment than Abcellera Biologics. However, Morgan Stanley is 1.79 times less risky than Abcellera Biologics. It trades about 0.16 of its potential returns per unit of risk. Abcellera Biologics is currently generating about 0.08 per unit of risk. If you would invest  10,342  in Morgan Stanley on September 29, 2024 and sell it today you would earn a total of  2,334  from holding Morgan Stanley or generate 22.57% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Significant
Accuracy	100.0%
Values	Daily Returns

Morgan Stanley  vs.  Abcellera Biologics

Morgan Stanley

Risk-Adjusted Performance

12 of 100

Good

Compared to the overall equity markets, risk-adjusted returns on investments in Morgan Stanley are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively abnormal basic indicators, Morgan Stanley unveiled solid returns over the last few months and may actually be approaching a breakup point.

Abcellera Biologics

Risk-Adjusted Performance

5 of 100

Modest

Compared to the overall equity markets, risk-adjusted returns on investments in Abcellera Biologics are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. Despite quite unsteady fundamental indicators, Abcellera Biologics disclosed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Morgan Stanley and Abcellera Biologics

The main advantage of trading using opposite Morgan Stanley and Abcellera Biologics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Morgan Stanley position performs unexpectedly, Abcellera Biologics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Abcellera Biologics will offset losses from the drop in Abcellera Biologics' long position.

The idea behind Morgan Stanley and Abcellera Biologics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.